论文部分内容阅读
目的 :对阿米卡星 (AMK)与苯唑西林 (OXA)合用健康者和急性白血病患者体内药代动力学进行研究。方法 :微量微生物法测定AMK血、尿药浓度。结果 :单用与合用AMK的药时曲线均符合二房室模型 ,健康者体内AMK单用与合用药代动力学参数分别为 :K10 ( 0 .5 5± 0 .2 2 )和 ( 0 .4 2± 0 .0 3 )h-1(P <0 .0 5 ) ,t1/ 2 β( 2 .1 1± 0 .1 6)和 ( 3 .0 0± 0 .4 1 )h(P <0 .0 1 ) ;AUC( 5 4 .7± 3 .90 )和 ( 69.1 5± 4 .91 ) μg·h·ml-1(P <0 .0 0 1 ) ;急性白血病患者体内 ,AMK单用与合用药代动力学参数分别为 :K12( 0 .0 6± 0 .2 6)和 ( 1 .0 6± 0 .1 0 )h-1(P <0 .0 5 ) ,K2 1( 1 .4 7± 0 .64 )和 ( 1 .84± 0 .2 2 )h-1(P <0 .0 5 )。K10 ( 0 .71± 0 .0 5 )和 ( 0 .5 4± 0 .0 4 )h-1(P <0 .0 5 ) ,t1/ 2 β( 1 .62± 0 .1 9)和 ( 2 .2 2± 0 .0 9)h(P <0 .0 1 ) ,AUC( 3 9.92± 4 .2 0 )和 ( 5 1 .5 3± 3 .0 0 ) μg·h·ml-1(P<0 .0 0 1 )。结论 :健康者和急性白血病患者体内OXA对AMK的药代动力学均有显著的影响。
OBJECTIVE: To study in vivo pharmacokinetics of amikacin (AMK) and oxacillin (OXA) in healthy and acute leukemia patients. Methods: The concentration of AMK blood and urine was determined by microbiological method. Results: The pharmacokinetic parameters of AMK alone and combined with AMK were in accordance with the two-compartment model. The pharmacokinetic parameters of AMK alone and in combination were K10 (0.55 ± 0.222) and (0.4 2 ± 0. 0 3) h-1 (P <0.05), t1 / 2 β (2 .1 ± 0.16) and (3.00 ± 0.41) h (P <0.01); AUC (54.7 ± 3.90) and (69.1 ± 4.91) μg · h · ml-1 The pharmacokinetic parameters of K12 (0.06 ± 0.226) and (1.06 ± 0.10) h-1 (P <0.05) and K2 1 ( 1. 47 ± 0.64) and (1.84 ± 0.22) h-1 (P <0.05). K10 (0 .71 ± 0 .0 5) and (0 .4 ± 0 .0 4) h-1 (P <0.05), t1 / 2β (1.62 ± 0.19) and (2 .2 ± 0. 0 9) h (P <0.01), AUC (39.92 ± 4.20) and (51.33 ± 3.00) μg · h · ml- 1 (P <0 .0 0 1). CONCLUSIONS: OXA in healthy and acute leukemia patients has a significant effect on the pharmacokinetics of AMK.